AGP
CYTK icon

Artia Global Partners’s Cytokinetics CYTK Stock Holding History

Artia Global Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-400,500
Closed -$33.4M – 52
2023
Q4 		$33.4M Buy
+400,500
New +$14.5M 9.73% 5

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Artia Global Partners's CYTK Position: Q2 2026 in Review

Artia Global Partners increased its Cytokinetics (CYTK) stake by 334% in Q2 2026, buying an estimated $3.91M and bringing the position to 70,700 shares worth $6.02M. The position accounts for 1.11% of the portfolio, ranked #19.

Artia Global Partners first reported a position in CYTK in Q4 2023 and has held it in 4 quarters since. The position peaked at $6.28M in Q1 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Artia Global Partners held 70,700 shares of Cytokinetics worth $6.02M as of Q2 2026.
  • Artia Global Partners bought 54,400 Cytokinetics shares in Q2 2026, an estimated $3.91M.
  • Cytokinetics made up 1.11% of Artia Global Partners's portfolio in Q2 2026, its #19 holding.
  • Artia Global Partners first reported a position in Cytokinetics in Q4 2023 and has held it in 4 quarters since.
  • Artia Global Partners's Cytokinetics position peaked at $6.28M in Q1 2024.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Artia Global Partners's 13F filing for Q2 2026, filed 14 Aug 2026.